Literature DB >> 17412323

Cripto-1 expression in uveal melanoma: an immunohistochemical study.

Kandalam Mallikarjuna1, Pushparaj Vaijayanthi, Subramanian Krishnakumar.   

Abstract

Human Cripto, the founder member of the epidermal growth factor-Cripto-FRL1-Cryptic (EGF-CFC) family, plays an important role during early embryonic development and in particular in carcinogenesis and the development of cancer metastases. Cripto-1 is over-expressed in most cancers, but is absent or only weakly expressed in normal cells. For this reason, Cripto-1 could be of potential value in the targeted treatment. There is no information on the expression of Cripto-1 in human uveal melanoma. Cripto-1 reactivity was evaluated by immunohistochemistry on 36 archival uveal melanomas using the polyclonal antibody to Cripto-1. The tumors were divided in to 2 groups. There were 18 uveal melanomas with no intrascleral or extrascleral extension and 18 uveal melanomas with intrascleral/extrascleral extension/liver metastasis. Cripto-1 reactivity was correlated with tumor aggressiveness and cell type. Furthermore, we studied the immunolocalization of Cripto-1 in 4 uveal melanoma cell lines OCM-1, OCM-8, and 92-1, and OMM-1 and in 2 primary uveal melanocyte cultures. Cripto-1 was expressed in both the non-invasive and aggressive uveal melanomas. Cripto-1 was positive in the 4 uveal melanoma cell lines and absent in the primary uveal melanocyte cultures. Retinal tissue did not express Cripto-1. The results suggest that Cripto-1 is expressed in uveal melanoma, negative in the non-neoplastic ocular tissue and point to its use as a target for therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17412323     DOI: 10.1016/j.exer.2007.01.019

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  8 in total

1.  NANOTECHNOLOGY IN THE TREATMENT AND DETECTION OF INTRAOCULAR CANCERS.

Authors:  Ashwin Nair; Paul Thevenot; Wenjing Hu; Liping Tang
Journal:  J Biomed Nanotechnol       Date:  2008-12-01       Impact factor: 4.099

2.  Age-Dependent Association between Protein Expression of the Embryonic Stem Cell Marker Cripto-1 and Survival of Glioblastoma Patients.

Authors:  Berit B Tysnes; Hege A Satran; Sverre J Mork; Naira V Margaryan; Geir E Eide; Kjell Petersen; Luigi Strizzi; Mary J C Hendrix
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

3.  Elevated expression of Cripto-1 correlates with poor prognosis in non-small cell lung cancer.

Authors:  Chun-Hua Xu; Zhi-Hong Sheng; Hui-Di Hu; Ke-Ke Hao; Qing-Bo Wang; Li-Ke Yu
Journal:  Tumour Biol       Date:  2014-05-29

4.  Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma.

Authors:  Luigi Strizzi; Daniel E Abbott; David S Salomon; Mary J C Hendrix
Journal:  Cell Cycle       Date:  2008-05-05       Impact factor: 4.534

5.  Expression and functional role of CRIPTO-1 in cutaneous melanoma.

Authors:  A De Luca; L Lamura; L Strizzi; C Roma; A D'Antonio; N Margaryan; G Pirozzi; M-Y Hsu; G Botti; E Mari; M J C Hendrix; D S Salomon; N Normanno
Journal:  Br J Cancer       Date:  2011-08-23       Impact factor: 7.640

6.  CRIPTO-1 Is Immunolocalized in the Syncytiotrophoblast of Ampullary Pregnancies.

Authors:  Fábio Roberto Cabar; Pedro Paulo Pereira; Carla Letícia Bandeira; Estela Bevilacqua; Regina Schultz; Rossana Pulcineli Vieira Francisco
Journal:  Biomed Res Int       Date:  2022-04-08       Impact factor: 3.411

7.  Cripto-1 vaccination elicits protective immunity against metastatic melanoma.

Authors:  M A Ligtenberg; K Witt; F Galvez-Cancino; A Sette; A Lundqvist; A Lladser; R Kiessling
Journal:  Oncoimmunology       Date:  2016-01-08       Impact factor: 8.110

8.  Expression of Cripto-1 predicts poor prognosis in stage I non-small cell lung cancer.

Authors:  Chunhua Xu; Qi Yuan; Huidi Hu; Wei Wang; Qian Zhang; Li Li; Jiwang Wang; Rusong Yang
Journal:  J Cell Mol Med       Date:  2020-07-22       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.